Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)
Trial details
- Registry ID
- NCT04845620
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as ARQ-151
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)NCT04845620 | ARQT | Phase 3 | Completed | 2023-06-01Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |